ABBV Debt & Cash Flow

DividendWave

05-05

$AbbVie(ABBV)$ debt (10-Q)

Net debt ~$56 B at the end of the quarter

Net debt increased ~$9B (ImmunoGen acquisition)

$15 B new debt issued (connected to ImmunoGen and proposed Cerevel acquisitions)

$9.2 billion acquisition cost of ImmunoGen, Feb12

Image

$15 B "issued debt in connection with the acquisition of ImmunoGen and proposed acquisition of Cerevel Therapeutics"

I had previously "guessed" it would have maturities 2027+ which is now confirmed

Details as follows:

Image

"The total fair value of the consideration transferred to owners of ImmunoGen common stock was $9.8 billion ($9.2 billion, net of cash acquired)"

Cerevel Therapeutics Holdings acquisition expected within 2024, for ~$8.7 B

Image

ABBV Cash Flow

Slightly worsening OCF in 1Q

49% dividend payout

Image

https://twitter.com/DividendWave/status/1786735423395397694

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

ZoePaul
05-06
ZoePaul
👍🏼
Diego Degese
05-06
Diego Degese
👍

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":302541683998728,"tweetId":"302541683998728","gmtCreate":1714868567689,"gmtModify":1714962271225,"author":{"id":4119422390989172,"authorId":4119422390989172,"authorIdStr":"4119422390989172","name":"DividendWave","avatar":"https://community-static.tradeup.com/news/d0c902179631e815f3ee1e4cd8ad0708","vip":8,"userType":8,"introduction":"Dividend growth stocks analysis\nGraphs/data to be a better investor\nSome growth and crypto","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[{"img":"https://community-static.tradeup.com/news/32f26b6b1950fcab21bb2d010f780209","width":"900","height":"483"},{"img":"https://community-static.tradeup.com/news/82d0cd7398f314efe2c05aeb15b12759","width":"680","height":"195"},{"img":"https://community-static.tradeup.com/news/a491acf57d5101710eef99f9e7288c5f","width":"680","height":"382"},{"img":"https://community-static.tradeup.com/news/db20237084d2218f0cd574d8984c98fd","width":"680","height":"320"}],"coverImages":[{"img":"https://community-static.tradeup.com/news/32f26b6b1950fcab21bb2d010f780209","width":"900","height":"483"},{"img":"https://community-static.tradeup.com/news/82d0cd7398f314efe2c05aeb15b12759","width":"680","height":"195"},{"img":"https://community-static.tradeup.com/news/a491acf57d5101710eef99f9e7288c5f","width":"680","height":"382"}],"title":"ABBV Debt & Cash Flow","html":"<html><head></head><body> <a data-mention-id=\"ABBV\" class=\"teditor-mention\" data-mention-name=\"AbbVie\" href=\"https://ttm.financial/S/ABBV\">$AbbVie(ABBV)$</a> debt (10-Q) Net debt ~$56 B at the end of the quarterNet debt increased ~$9B (ImmunoGen acquisition)$15 B new debt issued (connected to ImmunoGen and proposed Cerevel acquisitions)$9.2 billion acquisition cost of ImmunoGen, Feb12<img alt=\"Image\" title=\"Image\" src=\"https://community-static.tradeup.com/news/32f26b6b1950fcab21bb2d010f780209\" tg-width=\"900\" tg-height=\"483\">Image$15 B \"issued debt in connection with the acquisition of ImmunoGen and proposed acquisition of Cerevel Therapeutics\"I had previously \"guessed\" it would have maturities 2027+ which is now confirmedDetails as follows:<img alt=\"Image\" title=\"Image\" src=\"https://community-static.tradeup.com/news/82d0cd7398f314efe2c05aeb15b12759\" tg-width=\"680\" tg-height=\"195\">Image\"The total fair value of the consideration transferred to owners of ImmunoGen common stock was $9.8 billion ($9.2 billion, net of cash acquired)\"Cerevel Therapeutics Holdings acquisition expected within 2024, for ~$8.7 B<img alt=\"Image\" title=\"Image\" src=\"https://community-static.tradeup.com/news/a491acf57d5101710eef99f9e7288c5f\" tg-width=\"680\" tg-height=\"382\">ImageABBV Cash FlowSlightly worsening OCF in 1Q49% dividend payout<img alt=\"Image\" title=\"Image\" src=\"https://community-static.tradeup.com/news/db20237084d2218f0cd574d8984c98fd\" tg-width=\"680\" tg-height=\"320\">Imagehttps://twitter.com/DividendWave/status/1786735423395397694</body></html>","htmlText":"<html><head></head><body> <a data-mention-id=\"ABBV\" class=\"teditor-mention\" data-mention-name=\"AbbVie\" href=\"https://ttm.financial/S/ABBV\">$AbbVie(ABBV)$</a> debt (10-Q) Net debt ~$56 B at the end of the quarterNet debt increased ~$9B (ImmunoGen acquisition)$15 B new debt issued (connected to ImmunoGen and proposed Cerevel acquisitions)$9.2 billion acquisition cost of ImmunoGen, Feb12<img alt=\"Image\" title=\"Image\" src=\"https://community-static.tradeup.com/news/32f26b6b1950fcab21bb2d010f780209\" tg-width=\"900\" tg-height=\"483\">Image$15 B \"issued debt in connection with the acquisition of ImmunoGen and proposed acquisition of Cerevel Therapeutics\"I had previously \"guessed\" it would have maturities 2027+ which is now confirmedDetails as follows:<img alt=\"Image\" title=\"Image\" src=\"https://community-static.tradeup.com/news/82d0cd7398f314efe2c05aeb15b12759\" tg-width=\"680\" tg-height=\"195\">Image\"The total fair value of the consideration transferred to owners of ImmunoGen common stock was $9.8 billion ($9.2 billion, net of cash acquired)\"Cerevel Therapeutics Holdings acquisition expected within 2024, for ~$8.7 B<img alt=\"Image\" title=\"Image\" src=\"https://community-static.tradeup.com/news/a491acf57d5101710eef99f9e7288c5f\" tg-width=\"680\" tg-height=\"382\">ImageABBV Cash FlowSlightly worsening OCF in 1Q49% dividend payout<img alt=\"Image\" title=\"Image\" src=\"https://community-static.tradeup.com/news/db20237084d2218f0cd574d8984c98fd\" tg-width=\"680\" tg-height=\"320\">Imagehttps://twitter.com/DividendWave/status/1786735423395397694</body></html>","text":"$AbbVie(ABBV)$ debt (10-Q) Net debt ~$56 B at the end of the quarter Net debt increased ~$9B (ImmunoGen acquisition) $15 B new debt issued (connected to ImmunoGen and proposed Cerevel acquisitions) $9.2 billion acquisition cost of ImmunoGen, Feb12 Image $15 B \"issued debt in connection with the acquisition of ImmunoGen and proposed acquisition of Cerevel Therapeutics\" I had previously \"guessed\" it would have maturities 2027+ which is now confirmed Details as follows: Image \"The total fair value of the consideration transferred to owners of ImmunoGen common stock was $9.8 billion ($9.2 billion, net of cash acquired)\" Cerevel Therapeutics Holdings acquisition expected within 2024, for ~$8.7 B Image ABBV Cash Flow Slightly worsening OCF in 1Q 49% dividend payout Image https://twitter.com/DividendWave/status/1786735423395397694","highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/302541683998728","repostId":0,"isVote":1,"tweetType":1,"viewCount":258,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["ABBV"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":true,"length":716,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":302871796150344,"gmtCreate":1714962824225,"gmtModify":1715150722369,"authorId":9000000000000335,"author":{"id":9000000000000335,"authorId":9000000000000335,"name":"ZoePaul","avatar":"https://static.tigerbbs.com/2bec56b183c9062aa6503216c12ee99f","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":302541683998728,"type":1,"supId":0,"prevId":0,"content":"👍🏼","text":"👍🏼","html":"👍🏼","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0},{"id":302871827476672,"gmtCreate":1714962822620,"gmtModify":1715150722307,"authorId":9000000000000559,"author":{"id":9000000000000559,"authorId":9000000000000559,"name":"Diego Degese","avatar":"https://community-static.tradeup.com/news/cd9f24d1c46c973464db8ae2adc00f74","vip":8,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":302541683998728,"type":1,"supId":0,"prevId":0,"content":"👍","text":"👍","html":"👍","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/302541683998728"}